Apollomics Inc. (NASDAQ:APLM) Sees Significant Drop in Short Interest

Apollomics Inc. (NASDAQ:APLM) was the recipient of a significant drop in short interest in February. As of February 13th, there was short interest totaling 14,705 shares, a drop of 16.5% from the January 29th total of 17,610 shares. Approximately 1.3% of the shares of the company are short sold. Based on an average daily volume of 15,434 shares, the short-interest ratio is currently 1.0 days. Based on an average daily volume of 15,434 shares, the short-interest ratio is currently 1.0 days. Approximately 1.3% of the shares of the company are short sold.

Apollomics Trading Up 3.6%

NASDAQ APLM opened at $20.51 on Thursday. The company’s 50 day simple moving average is $19.94 and its two-hundred day simple moving average is $16.96. Apollomics has a 1 year low of $3.66 and a 1 year high of $42.12.

Institutional Trading of Apollomics

An institutional investor recently bought a new position in Apollomics stock. Kestra Advisory Services LLC acquired a new position in shares of Apollomics Inc. (NASDAQ:APLM) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned approximately 0.40% of Apollomics at the end of the most recent quarter. Institutional investors and hedge funds own 19.13% of the company’s stock.

Analyst Ratings Changes

APLM has been the topic of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Apollomics in a report on Monday, December 29th. Wall Street Zen upgraded Apollomics from a “sell” rating to a “hold” rating in a research report on Saturday, January 17th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Apollomics presently has an average rating of “Sell”.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.